NC Biomatrix closes initial equity funding

Eindhoven, January 2022

NC Biomatrix has just closed its initial equity round of 1 mil € to finalise the required preclinical testing and to initiate the pilot clinical studies in the Netherlands and Germany. The investment round is led by DSM Venturing, the venture capital arm of Royal DSM, a global science-based company active in health, nutrition & bioscience. The round is joined by a group of angel investors. DSM’s business unit, DSM Biomedical, is a leading manufacturer of biomaterials worldwide, and has entered into a collaboration with NCBiomatrix.


Bob Guilleaume, CEO of NC Biomatrix, stated „We are very grateful for the support and trust the new investors have shown for NC Biomatrix. Together with the recent TakeOff2 loan from the Dutch NWO, we are in a position to bring the NC Biomatrix technology closer to clinical use and validation, which is
the next major milestone for the company.“